Short answer
What is Ipamorelin? Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that acts as a selective agonist of the ghrelin receptor GHS-R1a. It was described in the literature as the first selective growth hormone secretagogue, releasing growth hormone without significant elevation of ACTH or cortisol. It is sold as a lyophilized research powder and is not for human use.
What is Ipamorelin?
Ipamorelin is a small, synthetic growth hormone secretagogue. A secretagogue is a substance that stimulates the secretion of a hormone; in this case, the target is growth hormone released from the anterior pituitary. Ipamorelin is unusually small for a peptide of this class: it is a pentapeptide of just five amino acids, with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2.
The peptide was designed and characterized in the late 1990s as part of a research program aimed at growth hormone secretagogues, a class of compounds that had grown out of studies of the endogenous hormone ghrelin and its receptor. The landmark characterization paper described Ipamorelin as the first selective growth hormone secretagogue, based on its ability to release growth hormone while leaving other pituitary hormones largely unaffected [1].
Because of its small size and high selectivity, Ipamorelin has become a common subject of growth hormone research in laboratory settings. It is frequently studied in combination with GHRH receptor agonists, since the two act through complementary pathways.
Mechanism of action
Ipamorelin acts at the growth hormone secretagogue receptor type 1a (GHS-R1a), which is the same receptor activated by the endogenous hormone ghrelin. When the peptide binds this G-protein-coupled receptor on pituitary somatotrophs, it triggers growth hormone release.
Three properties of Ipamorelin are most relevant to researchers:
The distinction between potency and selectivity matters in research design. A compound can be highly potent at a receptor while still producing off-target effects; Ipamorelin's value as a research tool comes from combining receptor potency with a narrow endocrine profile.
The ghrelin system in growth hormone research
The ghrelin receptor is one of the three main inputs to the growth hormone axis, alongside GHRH and somatostatin. Endogenous ghrelin is a peptide hormone produced primarily by the stomach that signals hunger and, at the pituitary, stimulates growth hormone release. GHS-R1a is the receptor through which ghrelin and its synthetic analogs act.
Growth hormone secretagogues fall into two broad families:
Because these pathways converge on the same output, growth hormone, they are often studied together. Ipamorelin represents the ghrelin-receptor arm of this research, and its selectivity makes it a preferred tool when researchers want to stimulate growth hormone release without confounding changes in the stress-hormone (ACTH/cortisol) axis.
Ghrelin receptor pharmacology in practice
GHS-R1a is a member of the class A family of G-protein-coupled receptors and signals primarily through G alpha-q/11 to activate phospholipase C, raising intracellular calcium and triggering growth hormone exocytosis in somatotroph cells. The receptor is unusual in that it exhibits a high level of constitutive (basal) activity, meaning that even the unoccupied receptor generates some downstream signal. For researchers, this has two practical consequences. First, it means receptor antagonists are frequently used alongside agonists when the goal is to isolate agonist-specific effects. Second, it highlights why careful dose-response work is needed: with a constitutively active receptor, the difference between basal signaling and agonist-driven signaling can be subtle and must be measured rather than assumed.
The endogenous ligand ghrelin is an octanoylated 28-amino-acid peptide, but its receptor is also activated by a family of short synthetic peptides known as growth hormone secretagogues. Ipamorelin belongs to this synthetic family. Because the synthetic agonists are small and chemically defined, they are more convenient research reagents than the endogenous peptide, which requires acylation for activity and is unstable in solution. This practical advantage is one reason pentapeptide secretagogues like Ipamorelin appear so frequently in the growth hormone research literature.
Research history
The foundational publication on Ipamorelin is the 1998 study by Raun and colleagues in the European Journal of Endocrinology [1]. That work characterized the peptide across three experimental systems:
Subsequent studies extended the research into bone and metabolic physiology. One investigation reported that Ipamorelin, acting through its growth-hormone-releasing properties, increased longitudinal bone growth rate and body weight gain in adult female rats [2]. In that study, daily administration increased the bone growth rate from roughly 42 to 52 micrometers per day, a measurable gain in an adult skeleton that is normally quiescent, and it did so without a detectable change in total IGF-I, pointing to a direct growth-hormone-mediated effect on the growth plate rather than a systemic IGF-I surge. Another found that the growth hormone secretagogues Ipamorelin and GHRP-6 increased bone mineral content in adult female rats [3].
These bone-focused studies are representative of how secretagogue research connects the pituitary hormone axis to downstream physiology. Growth hormone stimulates both the liver to produce IGF-I and the skeleton and muscle directly through the growth hormone receptor. By stimulating growth hormone release at the pituitary, secretagogues engage this entire downstream cascade, which is why investigators in bone biology, body-composition research, and nitrogen-balance studies have all used them. It also explains why the ACTH/cortisol selectivity of Ipamorelin matters: a secretagogue that raised stress hormones would confound any experiment measuring body composition or bone remodeling, since glucocorticoids oppose those anabolic endpoints. Ipamorelin's narrow endocrine profile keeps the intervention specific to the growth hormone pathway.
Ipamorelin compared with related growth hormone secretagogues
Researchers choosing among growth hormone secretagogues weigh several factors:
Because GHRH receptor agonists and ghrelin receptor agonists drive growth hormone through different receptors, some protocols pair them. Pre-mixed blends such as the CJC-1295 + Ipamorelin Blend and the Tesamorelin + Ipamorelin Blend provide both mechanisms in a single lyophilized product for studies that call for dual-pathway stimulation.
How to evaluate research-grade Ipamorelin
The quality checks for Ipamorelin mirror those for any research peptide:
Because Ipamorelin is a pentapeptide, it is economical to synthesize and routinely produced at high purity. Still, verifying the analytical data before use protects the validity of downstream experiments.
Storage and handling
Standard lyophilized-peptide handling applies to Ipamorelin:
For a full laboratory protocol, see our peptide reconstitution and laboratory handling guide.
Summary
Ipamorelin is a pentapeptide ghrelin receptor agonist characterized as the first selective growth hormone secretagogue. Its defining properties are potency at GHS-R1a, a narrow endocrine profile that spares ACTH and cortisol, and documented downstream effects on bone and metabolism in animal research. As with all research peptides, verify HPLC purity, mass-spectrometry identity, and batch-specific COA, and follow standard lyophilized-peptide handling protocols.
FAQ
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the ghrelin receptor GHS-R1a.
How does Ipamorelin work?
It activates GHS-R1a on the pituitary to release growth hormone, without significant elevation of ACTH or cortisol.
Is Ipamorelin the same as GHRP-6?
No. Both are growth hormone secretagogues, but Ipamorelin is more selective, sparing the ACTH/cortisol response at suprathreshold doses.
What purity should research-grade Ipamorelin have?
At least 99% by HPLC, identity confirmed by mass spectrometry, and a batch-specific COA.